LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-07-01
|
| Series: | Lupus Science and Medicine |
| _version_ | 1797751339310120960 |
|---|---|
| author | Bindu Murthy Qihong Zhao Takafumi Ide Manoj Chiney Huynh Yen Thanh Bach Vineet Goti Coburn Hobar Urvi Aras |
| author_facet | Bindu Murthy Qihong Zhao Takafumi Ide Manoj Chiney Huynh Yen Thanh Bach Vineet Goti Coburn Hobar Urvi Aras |
| author_sort | Bindu Murthy |
| collection | DOAJ |
| first_indexed | 2024-03-12T16:46:00Z |
| format | Article |
| id | doaj.art-dd0bbd07c41a406194c485d98d89d279 |
| institution | Directory Open Access Journal |
| issn | 2053-8790 |
| language | English |
| last_indexed | 2024-03-12T16:46:00Z |
| publishDate | 2023-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Lupus Science and Medicine |
| spelling | doaj.art-dd0bbd07c41a406194c485d98d89d2792023-08-08T13:00:06ZengBMJ Publishing GroupLupus Science and Medicine2053-87902023-07-0110Suppl 110.1136/lupus-2023-KCR.257LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosusBindu Murthy0Qihong Zhao1Takafumi Ide2Manoj Chiney3Huynh Yen Thanh Bach4Vineet Goti5Coburn Hobar6Urvi Aras714Bristol-Myers Squibb, Princeton, New Jersey, USAOncology Discovery Biology, Bristol Myers Squibb, Lawrenceville, New Jersey, USA1Clinical Pharmacology, Bristol Myers Squibb, USA1Clinical Pharmacology, Bristol Myers Squibb, USA1Clinical Pharmacology, Bristol Myers Squibb, USA1Clinical Pharmacology, Bristol Myers Squibb, USA2Clinical Development, Bristol Myers Squibb, USA1Clinical Pharmacology, Bristol Myers Squibb, USA |
| spellingShingle | Bindu Murthy Qihong Zhao Takafumi Ide Manoj Chiney Huynh Yen Thanh Bach Vineet Goti Coburn Hobar Urvi Aras LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus Lupus Science and Medicine |
| title | LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus |
| title_full | LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus |
| title_fullStr | LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus |
| title_full_unstemmed | LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus |
| title_short | LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus |
| title_sort | lp 182 pharmacokinetics selectivity profile and exposure response relationship for efficacy and safety in a phase 2 study of deucravacitinib an oral selective allosteric tyk2 inhibitor in patients with systemic lupus erythematosus |
| work_keys_str_mv | AT bindumurthy lp182pharmacokineticsselectivityprofileandexposureresponserelationshipforefficacyandsafetyinaphase2studyofdeucravacitinibanoralselectiveallosterictyk2inhibitorinpatientswithsystemiclupuserythematosus AT qihongzhao lp182pharmacokineticsselectivityprofileandexposureresponserelationshipforefficacyandsafetyinaphase2studyofdeucravacitinibanoralselectiveallosterictyk2inhibitorinpatientswithsystemiclupuserythematosus AT takafumiide lp182pharmacokineticsselectivityprofileandexposureresponserelationshipforefficacyandsafetyinaphase2studyofdeucravacitinibanoralselectiveallosterictyk2inhibitorinpatientswithsystemiclupuserythematosus AT manojchiney lp182pharmacokineticsselectivityprofileandexposureresponserelationshipforefficacyandsafetyinaphase2studyofdeucravacitinibanoralselectiveallosterictyk2inhibitorinpatientswithsystemiclupuserythematosus AT huynhyenthanhbach lp182pharmacokineticsselectivityprofileandexposureresponserelationshipforefficacyandsafetyinaphase2studyofdeucravacitinibanoralselectiveallosterictyk2inhibitorinpatientswithsystemiclupuserythematosus AT vineetgoti lp182pharmacokineticsselectivityprofileandexposureresponserelationshipforefficacyandsafetyinaphase2studyofdeucravacitinibanoralselectiveallosterictyk2inhibitorinpatientswithsystemiclupuserythematosus AT coburnhobar lp182pharmacokineticsselectivityprofileandexposureresponserelationshipforefficacyandsafetyinaphase2studyofdeucravacitinibanoralselectiveallosterictyk2inhibitorinpatientswithsystemiclupuserythematosus AT urviaras lp182pharmacokineticsselectivityprofileandexposureresponserelationshipforefficacyandsafetyinaphase2studyofdeucravacitinibanoralselectiveallosterictyk2inhibitorinpatientswithsystemiclupuserythematosus |